CagriSema in type 2 diabetes: meta-analysis of six trials shows HbA1c and weight falls

The study

This is a systematic review and Bayesian meta-analysis published in Diabetes, Obesity & Metabolism. The authors searched PubMed, Embase, CENTRAL and ClinicalTrials.gov through 30 June 2026 for randomised controlled trials of CagriSema in type 2 diabetes. CagriSema combines cagrilintide with semaglutide.

Six trials were included, representing 4554 potentially eligible participants with type 2 diabetes. Results were split by CagriSema dose and by comparator. For HbA1c and body weight, the authors aligned the efficacy (trial-product) estimands where the trials reported enough detail. They checked treatment-policy estimates in sensitivity analyses. Bayesian random-effects models gave posterior medians with 95% credible intervals (CrIs).

What they found

Versus placebo, CagriSema 2.4 mg:

• HbA1c was lower. The between-group difference was -1.87 percentage points (95% CrI, -2.08 to -1.62).
• Body weight was lower. The between-group difference was -12.69 percentage points in percentage body-weight change (95% CrI, -13.78 to -11.61).
• Gastrointestinal adverse events were more frequent (RR, 2.27; 95% CrI, 1.81 to 3.00).
• Discontinuation because of adverse events was more frequent (RR, 3.16; 95% CrI, 1.50 to 6.87).

Versus semaglutide 2.4 mg:

• The additional HbA1c reduction was modest and uncertain (-0.21 percentage points; 95% CrI, -0.62 to 0.11). The interval includes zero.
• The additional body-weight reduction remained probable (-5.84 percentage points; 95% CrI, -10.08 to -2.15).
• For gastrointestinal events and discontinuation, the estimates against semaglutide were less precise.

The authors conclude that CagriSema gives substantial glycaemic and body-weight benefits versus placebo. They say its advantage over dose-matched semaglutide is more evident for body weight. They say comparative gastrointestinal tolerability and discontinuation risk remain uncertain.

How much weight to give it

The analysis pooled six randomised controlled trials. Against placebo, the credible intervals for HbA1c and body weight were relatively narrow. The estimate for discontinuation because of adverse events was wide (RR, 3.16; 95% CrI, 1.50 to 6.87), so its size is uncertain.

The comparison with semaglutide is less secure. The credible interval for extra weight loss is wide (-10.08 to -2.15). The HbA1c interval includes zero. The abstract does not report how many trials contributed to each comparison. It also does not report heterogeneity, risk of bias, follow-up length or funding. The abstract speaks of "potentially eligible participants" and does not report how many were analysed.

HbA1c and body weight are surrogate outcomes. The abstract reports no data on cardiovascular events, kidney outcomes or long-term safety. The authors describe the semaglutide comparison as uncertain for HbA1c and for tolerability. It is best read with caution until more data are available.

For your clinic

This analysis summarises CagriSema's effects versus placebo and dose-matched semaglutide in type 2 diabetes. It does not support an individual treatment decision. The abstract does not state the regulatory status of CagriSema, so check local availability and labelling separately.

The main message is that the advantage over dose-matched semaglutide is more evident for body weight; the additional HbA1c reduction was modest and uncertain (-0.21 percentage points; 95% CrI, -0.62 to 0.11), and the evidence for the weight result is still imprecise. Gastrointestinal tolerability deserves attention, since adverse events and discontinuations were higher than with placebo. Before changing practice, read the full paper for trial-level data, risk of bias and the dose groups. Also wait for guideline advice.